Heron Therapeutics Inc. (HRTX) has reached its enrollment target in a phase III study evaluating the efficacy of SUSTOL in the prevention of delayed-onset CINV following administration of highly emetogenic chemotherapy agent.
Forex – financial instrument.Forex news
Heron Therapeutics Inc. (HRTX) has reached its enrollment target in a phase III study evaluating the efficacy of SUSTOL in the prevention of delayed-onset CINV following administration of highly emetogenic chemotherapy agent.